In our meta-analysis, BRAF mutations did not show significant prognostic value for thyroid cancer in terms of OS (HR = 0.65; 95% CI: 0.46–0.94) or DFS (HR = 1.23; 95% CI: 0.66–2.29). This evidence concerns the gene BRAF and thyroid gland carcinoma.